Sarepta Therapeutics Sued for Securities Fraud Over Dangerous Drug Elevidys

A securities law firm has announced a lawsuit against Sarepta Therapeutics, Inc., the biopharmaceutical company behind the life-threatening treatment Elevidys, for allegedly misleading investors about the drug's risks. The complaint, filed on July 20, 2025, alleges that Sarepta repeatedly downplayed the dangers of Elevidys, which has caused fatal acute liver failure in patients, resulting in significant stock price declines. The lawsuit aims to recover losses for investors who purchased Sarepta securities between March 17, 2025, and July 18, 2025.

Key Takeaways:

• The lawsuit asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Sarepta securities.
• Sarepta allegedly touted the safety profile of Elevidys, stating that its benefits outweighed its risks, despite knowing about the treatment's fatal side effects.
• The stock price of Sarepta fell $27.81 per share on March 18, 2025, and $15.24 per share on June 15, 2025, after announcements about patient deaths and other incidents.
• The price of Sarepta stock fell more than 40% on July 18, 2025, after the company revealed a third patient death related to one of its investigational treatments.

Statistics:

• The stock price of Sarepta fell $27.81 per share on March 18, 2025 (27% decline).
• The stock price of Sarepta fell $15.24 per share on June 15, 2025 (42% decline).
• The stock price of Sarepta fell more than 40% on July 18, 2025.
• Investors have until August 25, 2025, to ask the Court to be appointed to lead the case.

Sources:

• GlobeNewswire, "Securities Law Firm Announces Class Action Lawsuit Against Sarepta Therapeutics, Inc. (NASDAQ: SRPT)", July 20, 2025.
• Dolgicer v. Sarepta Therapeutics, Inc., et al., No. 25-cv-05317 (U.S. District Court for the Southern District of New York).
• Bleichmar Fonti & Auld LLP.